Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG)
Study Details
Medical Condition
Study Phase
Intervention Type
Product
DateMedical ConditionRequirement Information
Date
AgeDateParticipation Requirements
Inclusion Criteria
Exclusion CriteriaInclusion CriteriaThe primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
| Location | Status |
|---|---|
Location United States, California Research Site Los Angeles, California, United States, 90078 | Status Recruiting |
Location United States, California Research Site San Francisco, California, United States, 94143 | Status Recruiting |
Location United States, Illinois Research Site Chicago, Illinois, United States, 60611 | Status Recruiting |
Location United States, Massachusetts Research Site Boston, Massachusetts, United States, 02115 | Status Recruiting |
Location United States, North Carolina Research Site Chapel Hill, North Carolina, United States, 27514 | Status Recruiting |
Location United States, Ohio Research Site Akron, Ohio, United States, 44308 | Status Recruiting |
Location United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19104 | Status Recruiting |
Location United States, Texas Research Site Denton, Texas, United States, 76208 | Status Recruiting |
Location Japan Research Site Itabashi-ku, Japan, 173-0003 | Status Recruiting |
